The areas around each of Indiana’s research university campuses—Bloomington, Indianapolis, Lafayette and South Bend—all boast outsize concentration of life sciences workers. Yet the state still lags on research, development and investment funding.
An Indianapolis-based biotech company plans to use $2.75 million in new funding to begin commercial production of its algae-based nutritional supplements, the firm announced Monday.
Attempts to build the sector are making headway, but Indiana still lags leading states.
While life sciences companies don’t rack up huge jobs numbers, their relatively high pay means that every job they create is worth two in the rest of the private sector.
In this age of austerity, there’s almost no chance of Indianapolis hospitals creating a Cleveland Clinic-like hub of innovation.
The institute aims to attract 100 new scientists to Indiana to conduct research and development work aimed at launching new therapies for metabolic diseases.
Local providers will increasingly look for help from IT firms like Indigo Biosystems Inc. and VoCare Inc. as part of a coming wave of health IT innovation that is likely to mirror the IT revolution that began 30 years ago.
While Indiana’s governor, legislature and life sciences executives are united behind the proposed Indiana Biosciences Research Institute, the state of Michigan has a cautionary tale to tell about such an effort.
The $360 million initiative will be formally launched on Thursday by Gov. Mike Pence, executives of five major life sciences companies and officials of the state’s research universities.
The future of Indiana’s sprawling health care and life sciences industry might be threatened by an unlikely source: smartphone apps.
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues of venture capital, digital health innovations and research university entrepreneurship.
Panel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.
The following is an unedited transcript of the discussion.
The state's agriculture department under new Gov. Mike Pence is planning a push into the science behind food production by trying to build a network of university and commercial researchers for what's being called an Agriculture Innovation Corridor.
Frustrated by up-and-down state funding for startup life sciences companies, industry leaders are talking up a plan to create a dedicated funding stream that could total $30 million a year.
The life sciences industry in Indiana employs 55,500 workers paying average wages of more than $88,500 per year, according to new figures released Tuesday by Indianapolis-based life sciences development group BioCrossroads.
Local startups Esanex Inc. and Algaeon Inc. have received $500,000 and $250,000, respectively, from Indiana Seed Fund II, BioCrossroads’ second fund to help fledgling life sciences companies.
BioCrossroads CEO David Johnson has been chosen president and CEO of the Central Indiana Corporate Partnership, succeeding Mark Miles, who is leaving the CICP after seven years to become CEO of Hulman & Co.
BioCrossroads CEO David Johnson sees little conflict as he balances all three in promoting and investing in Indiana life sciences firms
The amount of venture capital invested in medical-device and equipment companies nationally has declined each quarter this year, reaching levels not seen since 2004, according to data released Oct. 19 by the National Venture Capital Association and PricewaterhouseCoopers.
Eli Lilly CEO John Lechleiter on Tuesday called for creation of a “world-class” research institute in Indianapolis to bring together scientists from universities and corporations to develop new medical therapies and companies.
Even though the potential payoff for health care innovation is less certain these days, the business case for new ways to produce more food has never been stronger. That’s the analysis that lies behind BioCrossroads' new report an agricultural innovation.
